LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

26.51 4.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.76

Максимум

26.91

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+77.66% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	37M 2.9B
Предишно отваряне	22.43
Предишно затваряне	26.51

Настроения в новините

By Acuity

27%

73%

72 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.03.2026 г., 23:01 ч. UTC

Печалби

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5.03.2026 г., 21:54 ч. UTC

Печалби

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5.03.2026 г., 21:35 ч. UTC

Значими двигатели на пазара

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6.03.2026 г., 00:00 ч. UTC

Значими събития в новините

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5.03.2026 г., 23:27 ч. UTC

Пазарно говорене

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5.03.2026 г., 22:54 ч. UTC

Пазарно говорене

Печалби

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5.03.2026 г., 22:50 ч. UTC

Пазарно говорене

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5.03.2026 г., 22:48 ч. UTC

Печалби

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5.03.2026 г., 22:46 ч. UTC

Печалби

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5.03.2026 г., 22:44 ч. UTC

Печалби

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.03.2026 г., 21:35 ч. UTC

Печалби

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5.03.2026 г., 21:32 ч. UTC

Печалби

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5.03.2026 г., 21:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5.03.2026 г., 21:24 ч. UTC

Печалби

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5.03.2026 г., 21:23 ч. UTC

Печалби

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5.03.2026 г., 21:22 ч. UTC

Печалби

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5.03.2026 г., 21:21 ч. UTC

Печалби

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5.03.2026 г., 21:21 ч. UTC

Печалби

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5.03.2026 г., 21:20 ч. UTC

Печалби

Costco February Net Sales Were $21.69 B >COST

5.03.2026 г., 21:20 ч. UTC

Печалби

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5.03.2026 г., 21:20 ч. UTC

Печалби

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5.03.2026 г., 21:19 ч. UTC

Печалби

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5.03.2026 г., 21:18 ч. UTC

Печалби

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5.03.2026 г., 21:18 ч. UTC

Печалби

Costco 2Q Same-Store Sales Up 7.4% >COST

5.03.2026 г., 21:15 ч. UTC

Печалби

Costco 2Q EPS $4.58 >COST

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

77.66% нагоре

12-месечна прогноза

Среден 48.75 USD 77.66%

Висок 80 USD

Нисък 26 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

72 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.